GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
GRI Bio Announces Closing of $8.0 Million Public Offering
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio (NASDAQ:GRI) had its price target raised by analysts at Ascendiant Capital Markets from $35.00 to $36.00. They now have a "buy" rating on the stock.